Rituximab

Drug information

Prescribing information (Genentech)

Indications

Indolent NHL

• 375 mg/m2 iv qw x 4 followed by 375 mg/m2 iv q2m x 4

Ghielmini, M et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood 2004; 103:4416

• 375 mg/m2 iv qw x 4 followed by 375 mg/m2 iv qw x 4 every 6 months

Hainsworth, JD et al. Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma--a randomized phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2005; 23:1088

Chronic Lymphocytic Leukemia

• 375 mg/m2 iv qw x 4 wks q6m x 4 courses

Hainsworth, JD et al. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: A phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2003; 21:1746